The US Drug Enforcement Administration has formally approved the final plan for the production of test psychoactive substances for its contractors and controlled enterprises, once again raising the bar for the production of substances such as psilocybin, MDMA and DMT for the new year 2023.
For example, just a few months ago, the agency planned to raise the psilocybin production quota to 8,000 grams, which already represented a more than doubling of production. Now, the official plan states that in 2023, the agency requires the production of 12,000 grams of psilocybin for the needs of doctors and scientists. Similar increases were made to a number of other substances on the list, notably MDA, whose quota was raised from 200 grams to 12,000 grams, and 2C-B, which was increased from 25 grams to 5,100 grams. The quota for 5-MeO-DMT is now at 11,000 grams and the quota for MDMA is at 12,000 grams.
Of course, there has also been an increase in the agency's order for the production of cannabis, which, starting this year, can now also be supplied by private companies operating on the open market. More specifically, DEA plans to produce 6.7 million grams of cannabis flowers during 2023. In comparison, in 2022, service providers produced 3.2 million grams of cannabis flowers, and in 2021, less than 2 million grams, clearly indicating a significant increase in production.
Obviously, the growth of production plans is associated with the gradual opening of the service to the idea of regulating and supporting potentially therapeutic psychoactive substances, which include cannabis, as well as many natural psychedelics. In particular, interest in psilocybin, DMT and MDMA is directly related to the clinical tests that the country's health service is currently conducting in relation to these substances. Of these, information on the therapeutic effects of MDMA in the treatment of PTSD will become known this year, potentially paving the way for limited therapeutic legalization by 2024.